Fujian Shengdi completes Phase 3 test of GLP-1 drug HRS9531 in diabetes
The placebo-controlled trial finished on schedule with no posted HbA1c data yet, leaving the readout that will show whether HRS9531 matches China's crowded incretin field still ahead.
Executive Summary
- A pivotal Phase 3 trial of HRS9531 in newly diagnosed type 2 diabetes patients finished enrollment and treatment, moving to Completed status with its patient count unchanged from target.
- The trial is designed to show whether HRS9531 lowers blood sugar against placebo in patients whose diabetes is inadequately controlled by diet and exercise alone, the first-line population that anchors initial approval and adoption.
- No efficacy or safety data have posted yet, so the readout that determines whether the drug's blood-sugar and body-weight effects clear a competitive bar in China's incretin-drug landscape is still ahead.
- The sponsor's clean completion record across dozens of prior trials, and the trial's own steady progression from recruiting to completed without enrollment disruption, point to execution risk being low relative to the open question of what the data show.
The trial
NCT06650007 tested HRS9531 injection against placebo in 218 adults with type 2 diabetes mellitus whose blood sugar was inadequately controlled by diet and exercise alone, all naive to prior first-line pharmacotherapy. The trial ran in China, started dosing in November 2024, and moved to Completed status on the registry as of July 14, 2026. Its primary endpoint is the change in HbA1c (a measure of average blood sugar over roughly three months) from baseline to 36 weeks of treatment, with change in fasting plasma glucose, change in body weight, and two composite response-rate measures tracked as secondary endpoints. NCT06650007the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneNCT06650007
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Enrollment and timeline
Enrollment landed at 218 patients, up from an earlier 210-patient projection recorded in the registry, and that increase falls inside the routine range the trial's own operational benchmark flags only above a 20% move. The primary completion date has been revised twice over the trial's life, most recently settling at January 21, 2026, after an earlier registry entry had listed a 2025 date and, before that, a mid-2026 projection. The trial reached Completed status on schedule relative to that most recent guidance, with no gap between the stated primary completion window and the status change disclosed on the same day. NCT06650007the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneNCT06650007
What the data will show
No results have posted on ClinicalTrials.gov for this trial as of the current date. That leaves the central clinical question open: what HbA1c reduction HRS9531 produced against placebo, and whether the drug also moved the two composite response-rate secondaries, which combine glycemic control with a five-percent-or-greater weight loss threshold. Those composite measures matter because they test HbA1c control and weight loss together, the profile now standard for judging next-generation incretin drugs in diabetes. NCT06650007the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneNCT06650007
Competitive frame
HRS9531 sits in a Chinese and global type 2 diabetes field crowded with GLP-1 receptor agonists, SGLT2 inhibitors, and other incretin-pathway drugs, including Novo Nordisk's cagrilintide and Eli Lilly's orforglipron, both in active Phase 3 testing. None of the identified comparators share HRS9531's specific target, since that target has not been characterized in the competitive linkage data pulled here, so the comparison rests on indication and modality rather than mechanism class. Fujian Shengdi is also running a second Phase 3 tablet formulation of HRS9531 (not yet recruiting) and has one completed Phase 2 and one completed Phase 1 trial of the injectable in the same indication, giving the drug an internal, same-molecule track record heading into this pivotal readout. NCT06650007the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneNCT06650007
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.